skip to main |
skip to sidebar
Cardium and Tissue Repair Company's Excellarate : Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S.
March 17, 2008 - Cardium Therapeutics (Amex: CXM) and its subsidiary, Tissue Repair Company (TRC) reported that the Phase 2b MATRIX clinical study has been the focus of media attention in multiple regions across the U.S., including television news features in Florida, Pennsylvania, Arizona and Southern California. 
The MATRIX study is evaluating the safety and efficacy of Excellarate(TM) for the potential treatment of non-healing diabetic foot ulcers. Excellarate is a DNA-based topical gel that is being developed to be physician-administered once or twice to stimulate wound healing... Cardium Therapeutics' Press Release -
March 17, 2008 - Cardium Therapeutics (Amex: CXM) and its subsidiary, Tissue Repair Company (TRC) reported that the Phase 2b MATRIX clinical study has been the focus of media attention in multiple regions across the U.S., including television news features in Florida, Pennsylvania, Arizona and Southern California. 
The MATRIX study is evaluating the safety and efficacy of Excellarate(TM) for the potential treatment of non-healing diabetic foot ulcers. Excellarate is a DNA-based topical gel that is being developed to be physician-administered once or twice to stimulate wound healing... Cardium Therapeutics' Press Release -
